Abstract 5189
Background
Small cell lung cancer (SCLC) is a highly lethal disease. Recently, immunotherapy has demonstrated a benefit for a subgroup of patients beyond the second-line and in the first-line setting combined with chemotherapy. However, the majority of patients will not benefit and predictive biomarkers are urgently needed. High baseline neutrophil count (NC) and neutrophil-to-lymphocyte ratio (NLR) are unfavorable prognostic factors in SCLC and might also predict for lack of response to immunotherapy. There is data suggesting that activation of the HGF/MET pathway might contribute to the recruitment of immunosuppressor neutrophils in the tumor. Our aim was to evaluate the association between HGF serum levels (sHGF) and NC in SCLC and their impact on outcome.
Methods
Serum samples from SCLC patients were obtained before starting first-line treatment. We used the Quantikine Human HGF Immunoassay to quantify sHGF. All samples were run in duplicates. NC and NLR were obtained from blood test reports before treatment initiation. Statistical analysis was carried out using SPSS 22.0 and Prism 8.1.0. Correlation of variables was assessed by the Spearman’s correlation coefficient. Multivariate analysis was performed with the Cox regression method.
Results
Samples from 105 patients diagnosed with SCLC at our institution were included. 79.1% of the cases were male, 73.3% with extensive stage, and 31.4% had an ECOG score of ≥ 2. Median sHGF, NC and NLR were 1875.38pg/ml, 6440/µl and 5.1 respectively. Patients with baseline NLR > 4 or NC above median had worse median overall survival (mOS), with 7.9 vs 15.3 months (m) (p < 0.001) and 7.2 vs 15.3m (p < 0.001) respectively. sHGF above median values was also correlated with worse mOS (7.6 vs 12.8 m; p = 0.005). Baseline sHGF levels were positively correlated with NC (r = 0.34, p < 0.001). In the multivariate analysis for OS, sHGF and NC remained independently associated with poor outcome (HR 1.094; p = 0.001 and HR 1.18; p = 0.003 respectively).
Conclusions
Baseline HGF levels correlate with NC in SCLC, reinforcing the hypothesis of a plausible interplay between HGF/MET axis and the immune system. The role of these parameters as predictive biomarkers of response to immunotherapy in SCLC warrants further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Arriola: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): PGDx; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Lilly. All authors have declared no conflicts of interest.
Resources from the same session
2791 - Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
Presenter: Geoffroy Bilger
Session: Poster Display session 1
Resources:
Abstract
2916 - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Presenter: Enrica Capelletto
Session: Poster Display session 1
Resources:
Abstract
1427 - Final results of randomized phase II trial of metronomic vs weekly oral vinorelbine (OV) as first-line chemotherapy (CT) in advanced NSCLC patients unfit to platinum-based CT (P-CT): Tempo-Lung EudraCT Number: 2014-003859-61
Presenter: Dariusz Kowalski
Session: Poster Display session 1
Resources:
Abstract
3789 - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non–small-cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)
Presenter: Daniel Heudobler
Session: Poster Display session 1
Resources:
Abstract
1519 - Predicting Chemotherapy Toxicity in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Prospective Multicenter Study of the National Hospital Organization in Japan
Presenter: Masaki Kanazu
Session: Poster Display session 1
Resources:
Abstract
1874 - A prospective phase II trial of carboplatin (CBDCA) and nab-paclitaxel (nabPTX) for advanced non-small cell lung cancer (NSCLC) with interstitial lung disease (ILD)
Presenter: Toshiyuki Harada
Session: Poster Display session 1
Resources:
Abstract
3819 - Weekly Epirubicin as palliative treatment in elderly patients with malignant pleural mesothelioma.
Presenter: Paola Candido
Session: Poster Display session 1
Resources:
Abstract
3390 - Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates.
Presenter: Benjamin Solomon
Session: Poster Display session 1
Resources:
Abstract
5069 - Preliminary results from phase 1b study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Armando Santoro
Session: Poster Display session 1
Resources:
Abstract
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract